NCT00384033

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 638 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	Desvenlafaxine Succinate Sustained-Release (DVS SR)	50 mg tablet, once daily dosing for 8 weeks
DRUG	Desvenlafaxine Succinate Sustained-Release (DVS SR)	100 mg tablet, once daily dosing for 8 weeks
DRUG	Placebo	Matching placebo tablets and capsules, once daily dosing for 8 weeks
DRUG	Duloxetine 60 mg/day	60 mg capsule, once daily dosing for 8 weeks

Timeline

• Start date: 2006-09-01
• Primary completion: 2007-09-01
• Completion: 2007-09-01
• First posted: 2006-10-04
• Last updated: 2012-03-15
• Results posted: 2012-03-15

Locations

22 sites across 1 country: United States